Sanofi, Regeneron challenge Cabilly patents

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) filed an inter partes review (IPR) petition and a lawsuit last week challenging two Cabilly patents from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and the City of Hope (Duarte, Calif.).

Sanofi and Regeneron said they filed their suit in response to the "imminent threat of a lawsuit" by Genentech for infringement. Both Cabilly patents, which cover methods of antibody production, have been the target of several district court suits. ...